Trastuzumab (Herceptin) Clinical Trials
3 recruitingBiologic
Phase 22Phase 31
Showing 1–3 of 3 trials
Recruiting
Phase 3
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage I Breast Cancer AJCC v8Early-stage HER2+ Breast Cancer
Alliance for Clinical Trials in Oncology1,524 enrolled656 locationsNCT06876714
Recruiting
Phase 2
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
HER2-positive Metastatic Breast CancerAdvanced/Metastatic Breast Cancer
Sun Yat-sen University57 enrolled1 locationNCT07610720
Recruiting
Phase 2
Tucatinib and Trastuzumab in HER3-mutant and HER2-not Amplified Metastatic Breast Cancer
Metastatic Breast Cancer ( HER2 Negative)Unresectable Breast Cancer
Institut Curie20 enrolled9 locationsNCT07193394